» Articles » PMID: 28904206

A Disease-associated Frameshift Mutation in Caveolin-1 Disrupts Caveolae Formation and Function Through Introduction of a De Novo ER Retention Signal

Overview
Journal Mol Biol Cell
Date 2017 Sep 15
PMID 28904206
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Caveolin-1 (CAV1) is an essential component of caveolae and is implicated in numerous physiological processes. Recent studies have identified heterozygous mutations in the gene in patients with pulmonary arterial hypertension (PAH), but the mechanisms by which these mutations impact caveolae assembly and contribute to disease remain unclear. To address this question, we examined the consequences of a familial PAH-associated frameshift mutation in , P158PfsX22, on caveolae assembly and function. We show that C-terminus of the CAV1 P158 protein contains a functional ER-retention signal that inhibits ER exit and caveolae formation and accelerates CAV1 turnover in MEFs. Moreover, when coexpressed with wild-type (WT) CAV1 in MEFs, CAV1-P158 functions as a dominant negative by partially disrupting WT CAV1 trafficking. In patient skin fibroblasts, CAV1 and caveolar accessory protein levels are reduced, fewer caveolae are observed, and CAV1 complexes exhibit biochemical abnormalities. Patient fibroblasts also exhibit decreased resistance to a hypo-osmotic challenge, suggesting the function of caveolae as membrane reservoir is compromised. We conclude that the P158PfsX22 frameshift introduces a gain of function that gives rise to a dominant negative form of CAV1, defining a new mechanism by which disease-associated mutations in CAV1 impair caveolae assembly.

Citing Articles

Early proteostasis of caveolins synchronizes trafficking, degradation, and oligomerization to prevent toxic aggregation.

Morales-Paytuvi F, Fajardo A, Ruiz-Mirapeix C, Rae J, Tebar F, Bosch M J Cell Biol. 2023; 222(9).

PMID: 37526691 PMC: 10394380. DOI: 10.1083/jcb.202204020.


Defining the clinical validity of genes reported to cause pulmonary arterial hypertension.

Welch C, Aldred M, Balachandar S, Dooijes D, Eichstaedt C, Graf S Genet Med. 2023; 25(11):100925.

PMID: 37422716 PMC: 10766870. DOI: 10.1016/j.gim.2023.100925.


The building blocks of caveolae revealed: caveolins finally take center stage.

Kenworthy A Biochem Soc Trans. 2023; 51(2):855-869.

PMID: 37082988 PMC: 10212548. DOI: 10.1042/BST20221298.


Caveolae Mechanotransduction at the Interface between Cytoskeleton and Extracellular Matrix.

Sotodosos-Alonso L, Pulgarin-Alfaro M, Del Pozo M Cells. 2023; 12(6).

PMID: 36980283 PMC: 10047380. DOI: 10.3390/cells12060942.


Genes in pediatric pulmonary arterial hypertension and the most promising gene therapy.

Dai L, Du L Front Genet. 2022; 13:961848.

PMID: 36506323 PMC: 9730536. DOI: 10.3389/fgene.2022.961848.


References
1.
Mathew R, Huang J, Gewitz M . Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiol Rev. 2007; 15(3):143-9. DOI: 10.1097/01.crd.0000249381.49138.b9. View

2.
Schlegel A, Lisanti M . A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. J Biol Chem. 2000; 275(28):21605-17. DOI: 10.1074/jbc.M002558200. View

3.
Sinha B, Koster D, Ruez R, Gonnord P, Bastiani M, Abankwa D . Cells respond to mechanical stress by rapid disassembly of caveolae. Cell. 2011; 144(3):402-13. PMC: 3042189. DOI: 10.1016/j.cell.2010.12.031. View

4.
Liu L, Pilch P . A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem. 2007; 283(7):4314-22. DOI: 10.1074/jbc.M707890200. View

5.
Austin E, Loyd J . The genetics of pulmonary arterial hypertension. Circ Res. 2014; 115(1):189-202. PMC: 4137413. DOI: 10.1161/CIRCRESAHA.115.303404. View